Strides Pharma Science Balance Sheet Health
Financial Health criteria checks 4/6
Strides Pharma Science has a total shareholder equity of ₹20.7B and total debt of ₹25.2B, which brings its debt-to-equity ratio to 121.5%. Its total assets and total liabilities are ₹58.4B and ₹37.7B respectively. Strides Pharma Science's EBIT is ₹5.8B making its interest coverage ratio 1.8. It has cash and short-term investments of ₹3.0B.
Key information
121.5%
Debt to equity ratio
₹25.17b
Debt
Interest coverage ratio | 1.8x |
Cash | ₹2.97b |
Equity | ₹20.72b |
Total liabilities | ₹37.68b |
Total assets | ₹58.40b |
Recent financial health updates
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Recent updates
After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Aug 14Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
Apr 04Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Dec 23We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 02Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50
Jul 28Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)
Apr 13Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?
Mar 04These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?
Jan 26The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It
Jan 11Who Has Been Selling Strides Pharma Science Limited (NSE:STAR) Shares?
Dec 28Are Strides Pharma Science's (NSE:STAR) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 10Could The Strides Pharma Science Limited (NSE:STAR) Ownership Structure Tell Us Something Useful?
Nov 25Financial Position Analysis
Short Term Liabilities: STAR's short term assets (₹29.7B) exceed its short term liabilities (₹28.8B).
Long Term Liabilities: STAR's short term assets (₹29.7B) exceed its long term liabilities (₹8.9B).
Debt to Equity History and Analysis
Debt Level: STAR's net debt to equity ratio (107.2%) is considered high.
Reducing Debt: STAR's debt to equity ratio has increased from 116.2% to 121.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable STAR has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: STAR is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 37.7% per year.